NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (NASDAQ: TLRY and TSX: TLRY) is building on the ...

“Users have long desired a small, discreet, and fully featured in-the-ear hearing aid. Through our innovative RightFit™ ...

FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following ...

New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of ...

Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH ® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue ...

Compass intends to use the net proceeds from the offering to conduct initial preparations for commercial readiness, to fund research and clinical development of its product candidates, and for general ...

Financial Results for the Quarter Ended June 30, 2025 Kyverna reported $211.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which the Company expects will provide a ...

CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

For the quarter ended June 30, 2025, the Company reported revenues of approximately $303,000, which consisted primarily of BioCosmeceutical sales in connection with its exclusive supply agreement with ...

Net loss was $23.0 million, or $0.31 per basic and diluted share, for the second quarter of 2025. This net loss includes non-cash charges of $3.4 million that consisted primarily of share-based ...

IND Cleared for ERAS-4001: In June 2025, Erasca announced clearance of an investigational new drug (IND) application with the United States Food and Drug Administration (FDA) for its pan-KRAS ...

Maze continues to enroll patients in the Phase 2 HORIZON trial of MZE829. The trial includes a broad population of patients with AMKD, including those with diabetes, those with non-diabetic kidney ...